Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $191.6 million.

  • Ani Pharmaceuticals' Operating Expenses rose 1345.68% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.9 million, marking a year-over-year increase of 3883.35%. This contributed to the annual value of $613.8 million for FY2024, which is 3954.73% up from last year.
  • Ani Pharmaceuticals' Operating Expenses amounted to $191.6 million in Q3 2025, which was up 1345.68% from $197.5 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Operating Expenses peaked at $197.5 million during Q2 2025, and registered a low of $51.5 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $116.9 million, with a median of $104.1 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Operating Expenses crashed by 1065.68% in 2021 and then skyrocketed by 6254.57% in 2022.
  • Ani Pharmaceuticals' Operating Expenses (Quarter) stood at $84.7 million in 2021, then grew by 9.17% to $92.4 million in 2022, then surged by 35.19% to $124.9 million in 2023, then soared by 56.05% to $195.0 million in 2024, then decreased by 1.73% to $191.6 million in 2025.
  • Its Operating Expenses stands at $191.6 million for Q3 2025, versus $197.5 million for Q2 2025 and $170.9 million for Q1 2025.